S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
The single greatest medical breakthrough of all time? (Ad)
What Should Investors Make of These 3 Dividend Cuts?
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
The single greatest medical breakthrough of all time? (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
The single greatest medical breakthrough of all time? (Ad)
Salesforce: Time to Snap it Up as the Market Buys the Dip?
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
The single greatest medical breakthrough of all time? (Ad)
What Should Investors Make of These 3 Dividend Cuts?
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
The single greatest medical breakthrough of all time? (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
The single greatest medical breakthrough of all time? (Ad)
Salesforce: Time to Snap it Up as the Market Buys the Dip?
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
The single greatest medical breakthrough of all time? (Ad)
What Should Investors Make of These 3 Dividend Cuts?
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
The single greatest medical breakthrough of all time? (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
The single greatest medical breakthrough of all time? (Ad)
Salesforce: Time to Snap it Up as the Market Buys the Dip?
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
The single greatest medical breakthrough of all time? (Ad)
What Should Investors Make of These 3 Dividend Cuts?
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
The single greatest medical breakthrough of all time? (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
The single greatest medical breakthrough of all time? (Ad)
Salesforce: Time to Snap it Up as the Market Buys the Dip?
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
NASDAQ:EQ

Equillium (EQ) Stock Forecast, Price & News

$0.63
+0.01 (+1.61%)
(As of 06/2/2023 ET)
Compare
Today's Range
$0.63
$0.65
50-Day Range
$0.49
$0.79
52-Week Range
$0.48
$3.20
Volume
62,633 shs
Average Volume
184,546 shs
Market Capitalization
$21.67 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.50

Equillium MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
932.1% Upside
$6.50 Price Target
Short Interest
Bearish
3.50% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.64) to ($0.46) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.18 out of 5 stars

Medical Sector

489th out of 983 stocks

Pharmaceutical Preparations Industry

237th out of 486 stocks


EQ stock logo

About Equillium (NASDAQ:EQ) Stock

Equillium, Inc. engages in the development of products for severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. Its product pipeline includes EQ001, which is a monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. The company was founded by Daniel Mark Bradbury, Bruce D. Steel, and Stephen Connelly on March, 2017 and is headquartered in La Jolla, CA.

Receive EQ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Equillium and its competitors with MarketBeat's FREE daily newsletter.

EQ Stock News Headlines

Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
Equillium (NASDAQ:EQ) PT Lowered to $5.50 at HC Wainwright
See More Headlines

EQ Price History

EQ Company Calendar

Last Earnings
3/23/2023
Today
6/02/2023
Next Earnings (Estimated)
8/21/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Fax
N/A
Employees
45
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$6.50
High Stock Price Forecast
$7.00
Low Stock Price Forecast
$5.50
Forecasted Upside/Downside
+932.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-62,430,000.00
Pretax Margin
-117.26%

Debt

Sales & Book Value

Annual Sales
$15.76 million
Book Value
$0.85 per share

Miscellaneous

Free Float
24,090,000
Market Cap
$21.67 million
Optionable
Not Optionable
Beta
1.19

Key Executives

  • Bruce D. Steel
    President, Chief Executive Officer & Director
  • Christine Zedelmayer
    Chief Operating Officer & Senior Vice President
  • Jason A. KeyesJason A. Keyes
    Chief Financial Officer
  • Stephen ConnellyStephen Connelly
    Director & Chief Scientific Officer
  • Joel M. Rothman
    Chief Development Officer













EQ Stock - Frequently Asked Questions

Should I buy or sell Equillium stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Equillium in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" EQ shares.
View EQ analyst ratings
or view top-rated stocks.

What is Equillium's stock price forecast for 2023?

3 Wall Street research analysts have issued 1 year price objectives for Equillium's shares. Their EQ share price forecasts range from $5.50 to $7.00. On average, they predict the company's stock price to reach $6.50 in the next twelve months. This suggests a possible upside of 932.1% from the stock's current price.
View analysts price targets for EQ
or view top-rated stocks among Wall Street analysts.

How have EQ shares performed in 2023?

Equillium's stock was trading at $1.06 at the beginning of 2023. Since then, EQ shares have decreased by 40.6% and is now trading at $0.6298.
View the best growth stocks for 2023 here
.

Are investors shorting Equillium?

Equillium saw a increase in short interest in May. As of May 15th, there was short interest totaling 724,100 shares, an increase of 14.6% from the April 30th total of 632,000 shares. Based on an average daily trading volume, of 160,800 shares, the short-interest ratio is currently 4.5 days. Approximately 3.5% of the company's stock are sold short.
View Equillium's Short Interest
.

When is Equillium's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023.
View our EQ earnings forecast
.

How were Equillium's earnings last quarter?

Equillium, Inc. (NASDAQ:EQ) announced its earnings results on Thursday, March, 23rd. The company reported $0.08 earnings per share for the quarter, topping analysts' consensus estimates of ($0.33) by $0.41. The business earned $15.76 million during the quarter, compared to analysts' expectations of $26 million.

What is Geoffrey A. Rotstein's approval rating as Equillium's CEO?

10 employees have rated Equillium Chief Executive Officer Geoffrey A. Rotstein on Glassdoor.com. Geoffrey A. Rotstein has an approval rating of 50% among the company's employees. This puts Geoffrey A. Rotstein in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 76.0% of employees surveyed would recommend working at Equillium to a friend.

When did Equillium IPO?

(EQ) raised $70 million in an IPO on Friday, October 12th 2018. The company issued 4,700,000 shares at a price of $14.00-$16.00 per share. Jefferies, Leerink Partners and Stifel served as the underwriters for the IPO.

What is Equillium's stock symbol?

Equillium trades on the NASDAQ under the ticker symbol "EQ."

Who are Equillium's major shareholders?

Equillium's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include JPMorgan Chase & Co. (4.71%) and Victory Capital Management Inc. (1.01%). Insiders that own company stock include Jason A Keyes, Jason A Keyes and Stephen Connelly.
View institutional ownership trends
.

How do I buy shares of Equillium?

Shares of EQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Equillium's stock price today?

One share of EQ stock can currently be purchased for approximately $0.63.

How much money does Equillium make?

Equillium (NASDAQ:EQ) has a market capitalization of $21.67 million and generates $15.76 million in revenue each year. The company earns $-62,430,000.00 in net income (profit) each year or ($0.84) on an earnings per share basis.

How can I contact Equillium?

Equillium's mailing address is 2223 AVENIDA DE LA PLAYA SUITE 108, LA JOLLA CA, 92037. The official website for the company is equilliumbio.com. The company can be reached via phone at (858) 240-1200 or via email at ir@equilliumbio.com.

This page (NASDAQ:EQ) was last updated on 6/3/2023 by MarketBeat.com Staff

My Account -